<DOC>
	<DOCNO>NCT02343926</DOCNO>
	<brief_summary>Primary Objective : To compare clinical efficacy gemigliptin vildagliptin add-on therapy metformin term change Hemoglobin A1c ( HbA1c ) reduction . Secondary Objectives : To compare safety tolerability gemigliptin vildagliptin : - Number patient experience least one episode hypoglycemia . - Number patient experience adverse event ( AE ) , serious adverse event ( SAE ) . - Assessment patient compliance define number tablet return patient .</brief_summary>
	<brief_title>Phase 3 Study Compare Efficacy Safety Gemigliptin Vildagliptin Add-on Therapy Metformin People With Type 2 Diabetes Inadequately Controlled With Metformin</brief_title>
	<detailed_description>The study consist 2 week screen 24 week treatment ( total 26 week ) . The protocol include screening period two week , randomize receive gemigliptin vildagliptin . Patients evaluate 4 mandatory visit study . Visit 1 : Week -2 ( screen ) Visit 2 : Week 0 ( randomization ) Visit 3 : Week 12 ( efficacy safety evaluation ) Visit 4 : Week 24 ( efficacy safety evaluation )</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Patients Type 2 diabetes mellitus . Patients inadequately control metformin maximal effective tolerate dose metformin least 12 week stable dose ≥1500 mg daily minimum ≥4 week prior study entry . Signed informed consent obtain prior study procedure . Exclusion criterion : Patients type 1 diabetes mellitus , gestational diabetes , diabetes secondary pancreatic disorder , drug chemical agent intake . Male female young 18 old 75 year old . Patients HbA1c ≤7 % ≥9.5 % . Patients 20 kg/m^2 &gt; body mass index ( BMI ) &gt; 40 kg/m^2 . Patients history hypersensitivity metformin . Patients history hypersensitivity vildagliptin . Lactose intolerance , lactase deficit , glucosegalactose malabsorption . Patients history acute metabolic complication lactic acidosis , diabetic precoma , diabetic ketoacidosis hyperosmolar hyperglycemic state within 3 month study entry . Patients treat insulin glucagonlike peptide1 ( GLP1 ) analogue . Patients treated thiazolidinediones ( pioglitazone ) last 6 month . Use systemic glucocorticosteroids ( exclude topical application inhale form ) 7 consecutive day within 3 month prior study entry . Patients impaired hepatic function ( alanine transaminase [ ALT ] , aspartate transaminase [ AST ] activity &gt; 1.5 time upper limit normal [ ULN ] ) . Patients impaired renal function ( serum creatinine concentration &gt; 135ɥmol/l men &gt; 110ɥmol/l female ) . Patients experience myocardial infarction , stroke , unstable angina coronary artery bypass surgery within 6 month prior screen , patient arrhythmia require treatment . Patients chronic heart failure IIIV functional class accord classification NYHA ( New York Heart Association ) . Patients take medicine thyroid hormone , warfarin , dicoumarin digoxin . Patients take sodium channel blocker SGLT2 inhibitor ( inhibitor sodium glucose transporter 2 ) last 6 week prior study entry . Known history alcohol drug abuse within 6 month prior screen . Pregnant woman breast feeding period . Women childbearing potential protected effective contraceptive method birth control . Men whose partner plan pregnancy . History hypersensitivity study drug drug similar chemical structure . Use investigational drug within 3 month prior study entry . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>